Tempest Therapeutics (NASDAQ:TPST) Lowered to Hold Rating by Zacks Research

Tempest Therapeutics (NASDAQ:TPST) was downgraded by equities research analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a report issued on Thursday,Zacks.com reports.

Separately, Wall Street Zen downgraded Tempest Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Tempest Therapeutics has a consensus rating of “Reduce”.

Tempest Therapeutics Trading Down 12.4%

Shares of NASDAQ TPST opened at $1.83 on Thursday. The company has a market cap of $26.24 million, a price-to-earnings ratio of -0.30 and a beta of -1.75. Tempest Therapeutics has a 12-month low of $1.50 and a 12-month high of $12.23. The stock’s 50 day simple moving average is $1.94 and its 200 day simple moving average is $3.35.

Tempest Therapeutics (NASDAQ:TPST) last announced its quarterly earnings results on Friday, May 15th. The company reported ($2.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($2.25). As a group, equities analysts forecast that Tempest Therapeutics will post -1.34 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Tempest Therapeutics news, CEO Matthew Angel bought 231,482 shares of the business’s stock in a transaction on Tuesday, March 24th. The shares were purchased at an average price of $2.16 per share, with a total value of $500,001.12. Following the purchase, the chief executive officer directly owned 231,482 shares of the company’s stock, valued at approximately $500,001.12. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. 6.28% of the stock is owned by insiders.

Institutional Trading of Tempest Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Sabby Management LLC bought a new stake in Tempest Therapeutics during the 4th quarter valued at $513,000. Vanguard Group Inc. raised its stake in Tempest Therapeutics by 20.8% during the 3rd quarter. Vanguard Group Inc. now owns 162,560 shares of the company’s stock valued at $1,671,000 after acquiring an additional 27,952 shares in the last quarter. Finally, Dimensional Fund Advisors LP bought a new stake in Tempest Therapeutics during the 4th quarter valued at $33,000. Institutional investors own 22.52% of the company’s stock.

Tempest Therapeutics Company Profile

Tempest Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of small molecule therapies for cancer and immune‐mediated diseases. Leveraging a proprietary drug discovery platform, Tempest advances programs designed to modulate tumor metabolism and enhance antitumor immunity. Its pipeline includes oral, selective inhibitors targeting pathways such as peroxisome proliferator‐activated receptor alpha (PPARα) and salt‐inducible kinase (SIK), with potential applications across solid tumors and hematologic malignancies.

The company’s lead candidate, TPST-1120, is a first‐in‐class PPARα antagonist designed to reprogram the tumor microenvironment by disrupting fatty acid oxidation in immune and cancer cells.